Healthcare and Medical Devices - Research and Markets - RSS Feed

China Portable Medical Electronic Devices Industry Report, 2010

press@researchandmarkets.com — Fri, 10 Sep 2010 14:48:12 GMT

Portable medical electronic devices can be mainly divided into home type and professional type, of which, the former covers electronic sphygmomanometer, electronic blood glucose meter, electronic hearing aids, etc , and the latter includes portable electrocardiograph, portable multi-parameter...

China Portable Medical Electronic Devices Industry Report, 2010

press@researchandmarkets.com — Fri, 10 Sep 2010 14:48:12 GMT

Introduction to Mental Health Treatment in Corrections

press@researchandmarkets.com — Fri, 10 Sep 2010 14:24:48 GMT

Drawing on his thirty-five years of field experience, Dr Emil Pinta has written a tremendously useful, practical, and sanity-preserving guide to the unique clinical conditions faced by psychologists and psychiatrists working in corrections For therapists treating patients in prisons, jails, or...

Aging, Cancer and Age-related Disease: Common Mechanisms?

press@researchandmarkets.com — Fri, 10 Sep 2010 14:19:30 GMT

This volume recognizes the rapidly expanding research linking aging, age-related diseases, and the delicate balance between neurodegeneration and cancer Wide perspectives on aging are covered, ranging from metabolic and cellular interventions in aging, oxidative stress resistance, protein folding...

Thymosins in Health and Disease: Second International Symposium

press@researchandmarkets.com — Fri, 10 Sep 2010 14:01:48 GMT

This volumes features contributions on the latest advances in the chemistry, biology and clinical applications of the thymosins from leading scientists and clinicians working in the field The use of chemically defined and synthesized molecules, rather than crude or partially purified extracts has...

Neuroendocrine Immunology in Rheumatic Diseases

press@researchandmarkets.com — Fri, 10 Sep 2010 13:57:12 GMT

As part of the Annals of the New York Academy of Sciences series, this volume features recent advances in the field of Neuroendocrine Rheumatology including: - the role of sleep on immune response, - the D hormone endocrine system - the effects of estrogens on immune rheumatic diseases - the role of...

Target Product Profiles 2010: Physician Insights on Key Attributes: Irritable Bowel Syndrome

press@researchandmarkets.com — Fri, 10 Sep 2010 13:18:50 GMT

Irritable Bowel Syndrome - A therapy that reduces abdominal pain and discomfort in a greater percentage of patients than alosetron for the treatment of non-constipation predominant irritable bowel syndrome Using Target Product Profiles in Your Market Strategy The Target Product Profiles...

Target Product Profiles 2010: Physician Insights on Key Attributes: Benign Prostatic Hyperplasia/Male Lower Urinary Tract Symptoms

press@researchandmarkets.com — Fri, 10 Sep 2010 11:59:51 GMT

Benign Prostatic Hyperplasia/Male Lower Urinary Tract Symptoms: An injectable therapy dosed every six months for the treatment of benign prostatic hyperplasia/male lower urinary tract symptoms Using Target Product Profiles in Your Market Strategy The Target Product Profiles qualitatively predict the...

Formulary Advantages in Parkinson’s Disease Drugs

press@researchandmarkets.com — Fri, 10 Sep 2010 10:47:26 GMT

Formulary Advantages in Parkinson’s Disease Drugs - Which clinical endpoints will drive uptake of emerging agents? Report Summary: Parkinson's disease (PD) is one of the most common neurodegenerative diseases in the elderly The launch of several new therapies and new formulations of key brands will...

The Directory of Health Care Group Purchasing Organizations 2010 Edition

press@researchandmarkets.com — Fri, 10 Sep 2010 10:18:03 GMT

This comprehensive directory profiles over 800 Purchasing Organizations that negotiate more than 65% of all health care products purchased by hospitals and related facilities, and the institutions they represent Listings include not only Group Purchasing Organizations, but also other types of...

Target Product Profiles 2010: Physician Insights on Key Attributes: Wet Age-Related Macular Degeneration

press@researchandmarkets.com — Fri, 10 Sep 2010 10:11:22 GMT

Wet Age-Related Macular Degeneration - A novel agent that requires dosing that is less frequent than monthly dosing for the treatment of wet age-related macular degeneration Using Target Product Profiles in Your Market Strategy The Target Product Profiles qualitatively predict the market potential...

Dealmaking and Industry Outlook in Niche Metabolic Diseases

press@researchandmarkets.com — Fri, 10 Sep 2010 09:00:30 GMT

Biologics will enjoy 12 years of marketing exclusivity under the newly enacted regulatory pathway for biosimilars in the United States, and opportunities for developing and marketing biobetters and enzyme replacement therapies (ERTs; biologics based on therapeutic recombinant enzymes) are great in...

Handbook of Diabetes, 4th Edition

press@researchandmarkets.com — Thu, 09 Sep 2010 15:36:59 GMT

Over three editions the Handbook of Diabetes has built a reputation as an essential practical manual on the assessment and management of patients with diabetes Previously written by Gareth Williams and John Pickup, the book has been completely revised by Rudy Bilous and Richard Donnelly to reflect...

Health & Wellness Promotion Benchmarking Series 2010

press@researchandmarkets.com — Thu, 09 Sep 2010 14:11:15 GMT

Health Coaching Benchmarks, 2010 Edition: Operations and Performance Data for Optimal Program ROI and Participant Health Status Despite the economy — and perhaps because of it — health and wellness coaching programs are flourishing Betting on behavior change, more employers, payors and providers are...

Pipeline and Commercial Insight: Moderate to Severe Chronic Nociceptive Pain - Anti-abuse opioids set to prosper

press@researchandmarkets.com — Thu, 09 Sep 2010 07:52:30 GMT

The moderate to severe chronic nociceptive pain market has boomed in the years since the removal of generic extended-release oxycodone from the US, growing in value to eclipse $10 billion. However, this reprieve will be short-lived with the pipeline and recently-launched drugs unable to fill the void left by generic erosion of OxyContin (controlled-release oxycodone, Purdue).

Scope

- Analysis of patient segmentation, epidemiology, current treatment approaches, the patient acquisition process and clinical unmet needs

- Breakdown of historic (200509) and future (201019) prescription sales across the seven major markets (US, Japan, France, Germany, Italy, Spain, UK)

- Review of key pipeline trends, issues in clinical trial design and the implications of Risk Evaluation and Mitigation Strategies required by the FDA

- Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and region-specific sales forecasts to 2019

Highlights of this title

Aided by continued growth of OxyContin and the launch of opioids incorporating anti-abuse technologies, the market is set to peak at $11.7 billion in 2012. Thereafter, the market will contract to reach $10.5 billion in 2019, when the effect of patent expiries on key brands offsets sales growth of new drugs.

Nucynta ER is the most clinically and commercially attractive pipeline drug, eclipsing the gold standard OxyContin. Backed by Johnson & Johnson, Nucynta ER is forecast to make a significant impact upon the market. Remoxy (extended-release oxycodone, King) and EG-P066 (extended-release morphine) are also both expected to feature as leading brands.

Expectations of the novel anti-NGF class have been dampened following revelations of the osteoarthritis-worsening side effects of tanezumab (RN624, Pfizer). Datamonitor predicts that tanezumab, an NGF monoclonal antibody, will reach the market; however, as a last line therapy in severe cancer pain.

Key reasons to purchase this title

Forecast Insight: Antidyslipidemics - Crestor drives growth before the Lipitor patent cliff hits

press@researchandmarkets.com — Thu, 09 Sep 2010 07:52:29 GMT

The antidyslipidemic market is approaching further genericization when in 2011, leading statin brand Lipitor will lose patent exclusivity and trigger decline of the entire market value. Clinical trials continue to produce an evidence base that justifies the dominant position held by statins and extends their reach into further indications.

Scope

- Analysis of revenue and volume sales of antidyslipidemic drug classes in the seven major markets

- Assess the impact of key patent expiries, such as Pfizer's Lipitor

- Forecast antidyslipidemic revenue and volume sales including performance of developmental agents and understand barriers to their uptake

- Understand the impact of clinical trials such as JUPITER on market dynamics and consider the epidemiologic trends in dyslipidemia

Highlights of this title

A rise in value of the antidyslipidemic market from 2008 to 2009 has been driven by acceleration in Crestor sales following the positive results from the JUPITER trial which led to the approval of Crestor in a new preventative indication.

Although past peak sales, Lipitor, the gold standard therapy and highest selling brand commanded 40% of antidyslipidemic revenues in 2009. This will change dramatically after the loss of its patent protection reducing Lipitor's market share to 9% by 2019, taking a large amount of the market's value with it.

Vytorin sales are down 29% from their 2007 peak after being sent into decline following the results of the ENHANCE and SEAS trials. Whilst sales growth of Zetia has been curbed by the same results, significant challenges remain for dyslipidemia therapies outside the statin class.

Key reasons to purchase this title

- Quantify and qualify antidyslipidemic sales in each of the seven major markets for 20062019

- Examine the future performance of leading antidyslipidemic brands and the growth of generics

- Understand the commercial landscape and challenges faced by pipeline agents

Brazil Pharmaceutical Market Overview - Expanding healthcare access drives double-digit sales growth

press@researchandmarkets.com — Thu, 09 Sep 2010 07:52:29 GMT

Brazil’s retail pharmaceutical market was valued at $12.6 billion in 2009, having grown by 14.3% between 2008 and 2009. Key growth drivers include the expanding population, improved access to healthcare, and the burgeoning middle class which is increasingly opting for branded drugs. Consequently, Big Pharma is targeting Brazil to off-set slowing sales growth in more developed markets.

Scope

- Overview of socioeconomic and demographic trends, healthcare system, regulation, pricing, reimbursement and intellectual property position in Brazil

- Assesses the size of Brazil’s pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies

- Examines Brazil’s generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion

- Quantifies Brazil’s R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis

Highlights of this title

Brazil spent 10.8% of its GDP on both retail and hospital prescribed pharmaceuticals in 2009, reflecting the government’s changing priorities, prioritizing healthcare including initiatives to expand access to medicines.

Intellectual property protection remains problematic for branded pharma, with issues associated with patent linkage, drawn out patent reviews, conflict between the two agencies involved in assessing patent applications, and the fact that there is no set period of data exclusivity.

Strong market growth in conjunction with improving regulatory standards has led to Brazil becoming a hotbed for investment from both multinational and domestic companies. Big Pharma players are gaining a stronger presence through M&A, expanding operations, and new product launches.

Key reasons to purchase this title

- Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access in Brazil.

- Quantify the size and growth of the pr

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019

press@researchandmarkets.com — Thu, 09 Sep 2010 07:52:29 GMT

The oncology market has witnessed a sizeable shift of focus away from cytotoxic therapies and antihormonal therapies towards the more lucrative targeted therapies and immunotherapies class in the last decade. This class boasts several of the top-selling anticancer brands overall, and has fueled most of the recent rapid growth of the oncology market as a whole.

Scope

- Forecast sales of every marketed cancer targeted therapy and immunotherapy in each of the seven major markets over the period 2009 to 2019

- Analysis and segmentation of the market at various levels including drug class, country, brand and company

- Comprehensive brand profiles and analysis for the key brands, including approval dates, patent expiries and all key events likely to impact sales

- Snapshot of the cancer targeted therapies and immunotherapies market in the rest of the world

Highlights of this title

Between 2010 and 2019, conditions in the oncology market will support relatively high growth rates for the targeted therapies and immunotherapies currently on the market. Combined sales in this class will grow at a CAGR of 6.6 % from $19.5 billion in 2009 to reach $36.8 billion in 2019.

Avastin (bevacizumab; Roche/Chugai) was the leading oncology brand in 2009. Despite a number of setbacks (including failures in Phase III trials in certain new indications) and potential threats, sales of Avastin will continue to grow, driven by further indication expansions and increasing uptake in existing indications and new territories.

With a dominant presence in three of the four highest incidence solid tumors and the highest incidence hematological malignancy, Roche dominates the cancer targeted therapies and immunotherapies market. This will continue through to 2019, driven by the strong performance of the company’s monoclonal antibody franchise.

Key reasons to purchase this title

- Quantify the performance of each of the marketed cancer targeted therapies and immunotherapies in the seven m

Insomnia Market Forecast

press@researchandmarkets.com — Thu, 09 Sep 2010 07:52:29 GMT

The availability of generic versions of Ambien (zolpidem, Sanofi-Aventis) in the US from April 2007 onwards has intensified competition for both existing and prospective players in the insomnia market. Following the discontinuation of three 5-HT antagonists in late-stage development over 20092010, orexin receptor antagonists now represent the most innovative candidates in the insomnia pipeline.

Key reasons to purchase this title

- Quantify the current and future size of the insomnia market in the seven major pharmaceutical markets.

- Identify potential licensing opportunities based on product portfolios and anticipated market needs.

- Understand the country-specific impact of key events in the insomnia market during the forecast period 2010 to 2019.

Moderate to Severe Chronic Nociceptive Pain Market Forecast

press@researchandmarkets.com — Thu, 09 Sep 2010 07:52:28 GMT

Cancer Targeted Therapies and Immunotherapies Market Forecast

press@researchandmarkets.com — Thu, 09 Sep 2010 07:52:28 GMT

Reducing Avoidable Emergency Room Visits: Approaches to Redirect Patients to Cost-Effective Care Settings - 45-Minute Webinar

press@researchandmarkets.com — Wed, 08 Sep 2010 10:54:11 GMT

Many emergency room visits are for conditions and diagnoses that could potentially be treated in more cost-effective settings With an eye on cost containment and patient satisfaction, many healthcare organizations are seeking to identify, by both diagnosis and patient population, these potentially...

Best Practices in Case Management Patient Contact, Monitoring and Follow-up - 45-Minute Webinar

press@researchandmarkets.com — Wed, 08 Sep 2010 10:46:01 GMT

With the increasing use of case management to manage chronic conditions and the investment needed to implement and fund case management programs, healthcare organizations need a carefully managed strategy to ensure the return on investment in such a program During Best Practices in Case Management...

Hospital Discharge Improvement Guide: How to Close Six Key Care Gaps and Reduce Readmissions

press@researchandmarkets.com — Wed, 08 Sep 2010 10:39:46 GMT

The hospital discharge is not a finite period of time but rather an ongoing process requiring planning and precision Without a coordinated approach, the exit from the hospital can be fraught with risk and result in adverse events and unnecessary readmissions The Hospital Discharge Improvement Guide:...

Home Visit Handbook: Structure, Assessments and Protocols for Medically Complex Patients

press@researchandmarkets.com — Wed, 08 Sep 2010 10:34:03 GMT

Visiting medically complex patients at home can shed light on health-related issues that might go undetected during an office visit, reducing the likelihood of unplanned admissions or emergency department visits by these patients The Home Visit Handbook: Structure, Assessments and Protocols for...

Nanoparticles for Bioimaging Patent Landscape 2010

press@researchandmarkets.com — Wed, 08 Sep 2010 10:29:14 GMT

IP Overview NP for bioimaging presents a patent landscape analysis of the nanoparticles in bioimaging field In the current development of imaging technologies, new contrast agents and tracers are necessary to improve visualization Nanoparticles appear to have the highest potential because they can...

CDK Inhibitors Patent Landscape - 2009/10

press@researchandmarkets.com — Wed, 08 Sep 2010 10:13:52 GMT

IP Overview CDK Inhibitors presents a patent landscape analysis of the CDK Inhibitor field One of the most exciting developments in the 90’s has been the elucidation of the molecular mechanisms that control the progression of cells through the division cycle The cell-cycle progression is composed of...